Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

51.57USD
21 May 2019
Change (% chg)

-- (--)
Prev Close
$51.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
203,537
52-wk High
$60.98
52-wk Low
$35.86

Lalwani, Narendra 

Dr. Narendra D. Lalwani, Ph.D., FAHA, DABT is Executive Vice President - Research & Development of the Company. He was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Dr. Lalwani was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Dr. Lalwani held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Dr. Lalwani is a Fellow of the American Heart Association (FAHA) and a diplomat of the American Board of Toxicology (DABT). Dr. Lalwani earned a Ph.D. in Biophysics from the University of Bombay (India) and an M.B.A from the University of Michigan Ross School of Business.

Basic Compensation

Total Annual Compensation, USD 390,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 858,978
Fiscal Year Total, USD 1,248,980

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --